Catalent, Inc.
CTLTDelisted Dec 18, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001596783
Catalent, Inc. was delisted on Dec 18, 2024; its insiders filed their last Form 4 on Dec 18, 2024; 472 institutions reported holding it in 13F filings for Q3 2024, worth $10.8B in total; Elliott Investment Management was the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Catalent, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Catalent, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Stahl Jack L | Director | 0 | Dec 18, 2024 | 0 |
| Classon Rolf A | Director | 0 | Dec 18, 2024 | 0 |
| Damelio Frank A | Director | 0 | Dec 18, 2024 | 0 |
| Morel Donald E Jr | Director | 0 | Dec 18, 2024 | 0 |
| Lucier Gregory T | Director | 0 | Dec 18, 2024 | 0 |
| Greisch John J | Executive Chair | 0 | Dec 18, 2024 | 0 |
| Carroll J Martin | Director | 0 | Dec 18, 2024 | 0 |
| Masanovich Matti | SVP, Chief Financial Officer | 0 | Dec 18, 2024 | 0 |
| Gennadios Aristippos | Group Pres. Pharma & Consumer | 0 | Dec 18, 2024 | 0 |
| Evoli Lisa | SVP, Chief HR Officer | 0 | Dec 18, 2024 | 0 |
| Maselli Alessandro | President & CEO | 0 | Dec 18, 2024 | 0 |
| Gunther Scott | SVP, Quality & Reg. Affairs | 0 | Dec 18, 2024 | 0 |
| Ferraro Joseph Anthony | SVP, General Counsel, CCO | 0 | Dec 18, 2024 | 0 |
| Okey Stephanie | Director | 0 | Dec 18, 2024 | 0 |
| Hatzfeld Michael | Chief Accounting Officer | 0 | Dec 18, 2024 | 0 |
| Barg Steven | Director | 0 | Dec 18, 2024 | 0 |
| Barber Michael J | Director | 0 | Dec 18, 2024 | 0 |
| Hopson Ricky | Pres. BioProduct Delivery, CoS | 0 | Dec 18, 2024 | 0 |
| Ryan Michelle R | Director | 0 | Dec 18, 2024 | 0 |
| McErlane David | Group President, Biologics | 0 | Dec 18, 2024 | 0 |
| Kreuzburg Christa | Director | 18,283 | Jan 29, 2024 | 0 |
| Fasman Steven L | EVP & Chief Admin Officer | 72,380 | Dec 12, 2023 | 0 |
| Arnold Jonathan | SVP, CCO & Div. Head BioP Del. | 55,896 | Dec 12, 2023 | 0 |
| Pravda Ricardo | Chief Transformation Officer | 29,522 | Dec 12, 2023 | 0 |
| Grippo Michael J | SVP, Strategy & Corp. Dev. | 23,725 | Dec 12, 2023 | 0 |
| Carletti Lorenzo | SVP Global Ops Ph & Cons Hlth | 8,505 | Dec 12, 2023 | 0 |
| Hawkeswood Thomas W | Pres. Pharma Prod Delivery Div | 7,412 | Dec 12, 2023 | 0 |
| Hunt Patricia | Pres. Consumer Health Div | 11,106 | Dec 12, 2023 | 0 |
| Lickfold Charles | SVP, CIO | 10,892 | Dec 12, 2023 | 0 |
| Crane Rosemary A | Director | 23,873 | Oct 31, 2023 | 0 |
| Flynn Karen | Director | 24,339 | Oct 31, 2023 | 0 |
| Balachandran Madhavan | Director | 27,441 | Oct 31, 2023 | 0 |
| Zayas Ricardo | SVP, Operations, Biologics NA | 6,223 | Aug 3, 2023 | 0 |
| Santiago Karen Murphy | VP & Chief Accounting Officer | 4,763 | Aug 3, 2023 | 0 |
| Gargiulo Mario | SVP, Ops, Biologics Europe | 5,676 | May 3, 2023 | 0 |
| Boerman Manja | Pres. BioModalities Division | 14,414 | May 3, 2023 | 0 |
| Zippelius Peter | Director | 11,979 | Oct 31, 2022 | 0 |
| Riley Michael A. | Pres. Bio Product Delivery Div | 6,592 | Aug 30, 2022 | 0 |
| Chiminski John R | Executive Chair | 229,888 | Aug 26, 2022 | 0 |
| Schmidt Kay A | SVP, Enterprise Functions | 17,388 | Aug 26, 2022 | 0 |
| Castellano Thomas P | SVP, Chief Financial Officer | 20,099 | Aug 26, 2022 | 0 |
| Whitlow Ricci S | President, CSS | 2,923 | Jan 24, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 30, 2024 (view filing) | Jul 29 | 1 day | Maselli AlessandroPresident & CEO | SSale | −9.09K | $58.76 | −$534.0K | −4.9%177.5K after | |
| Aug 5, 2024 (view filing) | Aug 2 | 3 days | Gennadios AristipposGroup Pres. Pharma & Consumer | SSale | −1.17K | $59.55 | −$69.6K | −1.0%113.7K after | |
| Aug 5, 2024 (view filing) | Aug 2 | 3 days | Evoli LisaSVP, Chief HR Officer | SSale | −3.86K | $59.67 | −$230.3K | −8.9%39.4K after | |
| Aug 5, 2024 (view filing) | Aug 2 | 3 days | Ferraro Joseph AnthonySVP, General Counsel, CCO | SSale | −608 | $59.58 | −$36.2K | −2.4%24.3K after | |
| Aug 5, 2024 (view filing) | Aug 2 | 3 days | Gunther ScottSVP, Quality & Reg. Affairs | SSale | −666 | $59.55 | −$39.7K | −1.7%39.6K after | |
| Aug 5, 2024 (view filing) | Aug 2 | 3 days | Hopson RickyPres. BioProduct Delivery, CoS | SSale | −662 | $59.56 | −$39.4K | −2.2%30.0K after | |
| Sep 27, 2024 (view filing) | Sep 26 | 1 day | McErlane DavidGroup President, Biologics | SSale | −1.99K | $59.97 | −$119.6K | −5.2%36.3K after | |
| Oct 21, 2024 (view filing) | Oct 18 | 3 days | Ferraro Joseph AnthonySVP, General Counsel, CCO | SSale | −320 | $59.97 | −$19.2K | −1.3%24.0K after | |
| Nov 14, 2024 (view filing) | Nov 11 | 3 daysLate | Ryan Michelle RDirector | SSale | −2.80K | $59.70 | −$167.2K | −20.5%10.8K after |